Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ARKGNYSEARCA:ARKKNASDAQ:EXAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARKGARK Genomic Revolution ETF$23.40-0.9%$25.45$21.56▼$31.16$1.38B1.642.66 million shs4.90 million shsARKKARK Innovation ETF$54.14-0.1%$57.99$36.85▼$68.43$5.94B1.899.14 million shs9.52 million shsEXASExact Sciences$45.67-3.0%$50.15$40.62▼$79.62$8.48B1.252.61 million shs1.52 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARKGARK Genomic Revolution ETF-3.07%+3.29%-13.10%-3.22%-17.05%ARKKARK Innovation ETF-0.07%+12.23%-10.07%-11.19%+7.74%EXASExact Sciences-3.02%+1.67%-7.29%-21.41%-28.37%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AN/AN/AEXASExact Sciences4.4063 of 5 stars4.51.00.04.73.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARKGARK Genomic Revolution ETF 2.73Moderate Buy$23.40N/AARKKARK Innovation ETF 2.60Moderate Buy$54.14N/AEXASExact Sciences 2.90Moderate Buy$70.8355.10% UpsideCurrent Analyst Ratings BreakdownLatest EXAS, ARKK, and ARKG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025EXASExact SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$52.002/26/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.002/24/2025EXASExact SciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$70.00 ➝ $73.002/20/2025EXASExact SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/20/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$70.00 ➝ $65.002/20/2025EXASExact SciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $65.001/23/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.001/13/2025EXASExact SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/13/2025EXASExact SciencesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AEXASExact Sciences$2.76B3.07$5.20 per share8.79$12.93 per share3.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARKGARK Genomic Revolution ETFN/AN/A0.00∞N/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/A41.12∞N/AN/AN/AN/AN/AEXASExact Sciences-$204.15M-$5.57N/A91.34N/A-37.29%-5.29%-2.45%5/6/2025 (Estimated)Latest EXAS, ARKK, and ARKG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/19/2025Q4 2024EXASExact Sciences-$0.29-$0.06+$0.23-$4.67$701.45 million$713.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AARKKARK Innovation ETFN/A0.00%N/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARKGARK Genomic Revolution ETFN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AEXASExact Sciences0.972.151.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences88.82%Insider OwnershipCompanyInsider OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences1.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARKGARK Genomic Revolution ETFN/A47.40 millionN/ANot OptionableARKKARK Innovation ETFN/A109.70 millionN/ANot OptionableEXASExact Sciences6,400185.76 million182.56 millionOptionableEXAS, ARKK, and ARKG HeadlinesRecent News About These CompaniesExact Sciences Co. (NASDAQ:EXAS) Shares Sold by Zevenbergen Capital Investments LLCMarch 25 at 7:32 AM | marketbeat.comWhy Exact Sciences Corporation (EXAS) is Among the Best Diagnostics Stocks to Invest in Right NowMarch 24 at 1:29 PM | insidermonkey.comThrivent Financial for Lutherans Takes Position in Exact Sciences Co. (NASDAQ:EXAS)March 24 at 4:06 AM | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 24 at 2:07 AM | marketbeat.com171,053 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Raymond James Financial Inc.March 22, 2025 | marketbeat.comExact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?March 21, 2025 | msn.comPrimecap Management Co. CA Decreases Stock Position in Exact Sciences Co. (NASDAQ:EXAS)March 21, 2025 | marketbeat.comShould You Invest in Exact Sciences Corp. (EXAS)?March 20, 2025 | msn.comProficio Capital Partners LLC Purchases Shares of 28,545 Exact Sciences Co. (NASDAQ:EXAS)March 20, 2025 | marketbeat.comNikko Asset Management Americas Inc. Sells 137,288 Shares of Exact Sciences Co. (NASDAQ:EXAS)March 18, 2025 | marketbeat.comWilliam Blair Investment Management LLC Lowers Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)March 18, 2025 | marketbeat.comSwiss National Bank Sells 25,800 Shares of Exact Sciences Co. (NASDAQ:EXAS)March 18, 2025 | marketbeat.com10,578 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Parnassus Investments LLCMarch 16, 2025 | marketbeat.comTredje AP fonden Has $791,000 Position in Exact Sciences Co. (NASDAQ:EXAS)March 16, 2025 | marketbeat.comExact Sciences (NASDAQ:EXAS) Now Covered by Analysts at Royal Bank of CanadaMarch 16, 2025 | americanbankingnews.comPostrock Partners LLC Purchases New Stake in Exact Sciences Co. (NASDAQ:EXAS)March 15, 2025 | marketbeat.comExact Sciences (NASDAQ:EXAS) Shares Down 6.4% - What's Next?March 14, 2025 | marketbeat.comRoyal Bank of Canada Begins Coverage on Exact Sciences (NASDAQ:EXAS)March 14, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Shares Sold by Erste Asset Management GmbHMarch 14, 2025 | marketbeat.comAGF Management Ltd. Invests $2.67 Million in Exact Sciences Co. (NASDAQ:EXAS)March 14, 2025 | marketbeat.comRBC Capital Initiates Coverage of Exact Sciences (EXAS) with Sector Perform RecommendationMarch 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyTariffs Won’t Stop These 3 Stocks From RisingBy Chris Markoch | March 5, 2025View Tariffs Won’t Stop These 3 Stocks From Rising3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow MarginsBy Leo Miller | March 19, 2025View 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow MarginsEXAS, ARKK, and ARKG Company DescriptionsARK Genomic Revolution ETF BATS:ARKG$23.40 -0.21 (-0.89%) Closing price 03/25/2025 03:45 PM EasternExtended Trading$23.56 +0.15 (+0.66%) As of 03/25/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.ARK Innovation ETF NYSEARCA:ARKK$54.14 -0.04 (-0.07%) Closing price 03/25/2025 04:10 PM EasternExtended Trading$54.15 +0.01 (+0.02%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The ARK Innovation ETF (ARKK) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that seeks long-term capital growth from companies globally involved with, or that benefit from, disruptive innovation. ARKK was launched on Oct 31, 2014 and is managed by ARK.Exact Sciences NASDAQ:EXAS$45.67 -1.42 (-3.02%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$45.83 +0.16 (+0.36%) As of 03/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
